Rachel Salazar
Sr Vice President R&D, Strategy & Operations, Bicara Therapeutics As an accomplished drug development executive, Rachel brings to Bicara more than two decades of experience as a strategic leader in both early and late-stage clinical development, advancing novel drugs in the clinic and expanding the value of marketed products.
About this speaker
As an accomplished drug development executive, Rachel brings to Bicara more than two decades of experience as a strategic leader in both early and late-stage clinical development, advancing novel drugs in the clinic and expanding the value of marketed products. She is currently leading the development of their first asset ficerafusp alfa (BCA101) as well as managing various functions such as research, translational medicine and project management.
Before joining Bicara, Rachel served as a global development lead at EMD Serono where her work centered on driving various early-stage IO clinical programs and leading key R&D pipeline collaborations. Before that, Rachel served at Takeda Oncology where she contributed to the development of various late-stage programs and expansion of approved products including Adcetris®. Earlier in her career, she worked in portfolio management across various therapeutic areas at Pfizer.
Skilled in R&D strategy and program leadership, Rachel is driven by science and dedicated to developing therapies that can transform patient care. She is passionate about building vibrant and adaptable teams that have a sense of purpose and aspire to make meaningful impacts on patient’s lives.
Rachel holds both a Bachelor’s and Master of Science in Biomedical Engineering from Washington University in St. Louis and Tufts University and earned her DHSc from Eastern Virginia Medical School.
